CorriXR Therapeutics is pioneering an innovative approach to cancer treatment through its advanced gene editing platform, which leverages CRISPR/Cas technology to target and disable specific genes responsible for drug resistance in tumor cells. The company is initially focusing on the NRF2 gene, a critical transcriptional regulator implicated in creating a pro-carcinogenic environment around tumors. By disabling the NRF2 gene, CorriXR aims to enhance the efficacy of existing chemotherapy treatments, particularly for solid tumors such as squamous cell carcinoma of the head and neck, as well as other cancers like lung, esophageal, pancreatic, melanoma, and glioblastoma.

To facilitate the delivery of its gene editing therapies, CorriXR employs a lipid nanoparticle system combined with direct intratumoral injection, which is designed to minimize off-target effects and improve treatment precision. Preclinical studies have demonstrated that targeting the NRF2 pathway can lead to significant tumor shrinkage and cell death when used in conjunction with chemotherapy. This innovative approach positions CorriXR Therapeutics at the forefront of oncology-focused biotherapeutics, aiming to optimize cancer treatment and overcome challenges associated with drug resistance.

United States

CorriXR Therapeutics is an oncology-focused biotherapeutics development company with a ground-breaking gene editing platform technology. The company is headquartered in Wilmington, Delaware, United States.

CorriXR Therapeutics

Company Details